Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Non-Alcoholic Fatty Liver Disease
A Randomized Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Improving Activity of Non-Alcoholic Fatty Liver Disease
1 other identifier
interventional
43
0 countries
N/A
Brief Summary
There is no effective therapy for non-alcoholic fatty liver disease (NAFLD), although intensive calorie restriction is typically recommended but dietary adherence is an issue. Currently, there are no studies had been focusing the effect of Modified Alternate Day Calorie Restriction in NAFLD patient focusing on changes in liver steatosis and fibrosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2015
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2017
CompletedFirst Submitted
Initial submission to the registry
December 16, 2018
CompletedFirst Posted
Study publicly available on registry
January 2, 2019
CompletedJanuary 2, 2019
December 1, 2018
2 years
December 16, 2018
December 29, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (9)
Change from baseline shear wave elastography (SWE) at 8 weeks
Through the intercostal approach, SWE measurements were performed in the right liver lobe, at the supine position with the right arm in maximal abduction. The sonographer, assisted by an ultrasonic time-motion image, located a liver portion of at least 6 cm thick, free of large vascular structures. Once the measurement area had been located, the sonographer pressed the probe button to start an acquisition. Patients were asked to hold their breath for about five seconds, while the stiffness of the region of interest was measured and 10 measurements were made for each patient and the median average value of those measurements was recorded in kilopascals (kPa: metric).
Change from baseline at 8-week
Change from baseline liver steatosis at 8 weeks
Ultra-sonographic measurements including liver steatosis and shear wave elastography (SWE) were performed with the SuperSonic Imagine's Aixplorer® Ultrasound machine (Super Sonic Image, Aix-en Provence, France). All measurements were performed by a single sonographer where the inter-observer agreement level with another experienced sonographer was 85%.
Change from baseline at 8-week
Concentration of high-density lipoprotein (HDL)
Blood samples (8-10 hours of fasting blood samples) were collected from participants at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in mmol/L.
Change from baseline at 8-week
Concentration of low-density lipoprotein (LDL)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in mmol/L.
Change from baseline at 8-week
Concentration of triglycerides (TG)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in mmol/L.
Change from baseline at 8-week
Concentration of total cholesterol (TC)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in mmol/L.
Change from baseline at 8-week
Concentration of fasting blood sugar (FBS)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in mmol/L.
Change from baseline at 8-week
Concentration of alanine aminotransferase (ALT)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in U/L.
Change from baseline at 8-week
Concentration of aspartate aminotransferase (AST)
Blood samples (8-10 hours of fasting blood samples) were collected at 8-10 am at baseline and 8-week post intervention for biochemical analysis. It was measured in U/L.
Change from baseline at 8-week
Secondary Outcomes (1)
Dietary plan adherence
At 8-week
Study Arms (2)
Calorie restriction (MACR)
EXPERIMENTALParticipants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
Control group
NO INTERVENTIONParticipants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
Interventions
This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
Eligibility Criteria
You may qualify if:
- Have elevated ALT or AST level (ALT \>41 or AST\>34 IU/L)
- No evidence of other forms of liver diseases
- For those with diabetes mellitus and dyslipidaemia, they must be on a stable therapy for at least 6 months prior to study enrolment
You may not qualify if:
- Significant alcohol consumption (\> 1 standard drink per day)
- Pregnancy
- Involvement in an active weight loss program or taking weight loss medications
- Substance abuse and significant psychiatric problems.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yeong Yeh Lee, MD, PhD
Universiti Sains Malaysia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Participants were blinded after assignment to interventions or control group.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 16, 2018
First Posted
January 2, 2019
Study Start
August 1, 2015
Primary Completion
July 31, 2017
Study Completion
October 1, 2017
Last Updated
January 2, 2019
Record last verified: 2018-12
Data Sharing
- IPD Sharing
- Will not share